We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

AMP 2017

Stop by the Promega Creative Confections Shop , Booth #1719, for a sampling of what collaborating with Promega could offer for your molecular diagnostic results.

  • Calvin L. Rampton Salt Palace Convention Center, Salt Lake City, UT.
  •  Thursday, November 16, 2017 – Saturday, November 18, 2017

Empower Your Assay Development!

Empower Your Assay Development! Taste test innovative products for:
  • New Automated Nucleic Acid Purification
  • Quantitation and Qualification for Downstream PCR and NGS Applications
  • New NGS Tools
  • PCR Master Mixes for Molecular Diagnostic Assays
  • Microsatellite Instability Analysis System (MSI) for Immuno-oncology research
  • Custom Products and Assays
AMP booth
Tumbler Mug
Attend Our Workshops during Corporate Workshop Day on Wednesday, November 15

Every workshop attendee will receive a special treat. Bring it to our booth for a chance to win an Apple Watch.

Workshop 1 8:00 - 8:50AM Room 251D
MSI as a Research Marker for Immunotherapeutic Response.
In clinical research, MSI is a biomarker that is proving to be increasingly important in understanding the most effective treatment methods for various types of cancers.
Presented by:
Dr. James R. Eshleman of Johns Hopkins University School of Medicine.
James R. Eshleman, MD, PhD Professor of Pathology and Oncology Associate Director, Molecular Diagnostics Laboratory
Workshop 2 9:00 - 9:50AM Room 251D
Personalized automation workflows for Maxwell® nucleic acid extraction of molecular oncology sample types such as ccfDNA from plasma
Oncology research increasingly focuses on how individual genetics influences treatment outcomes. This shift has increased in the number of samples and molecular analyses necessary to characterize an individual’s genetic state. The increased demand for molecular testing has driven the need for higher throughput, automated nucleic acid extraction solutions for a wide variety of oncology-related samples types such as blood, FFPE and circulating cell-free DNA (ccfDNA). Here we present a new adaptive, modular workflow for higher throughput, automated nucleic acid extraction and post extraction sample preparation for a variety of oncology-related sample types including ccfDNA from human plasma.
Presented by:
Sydnor Withers, Senior Automation Scientist, Promega Corporation.
Workshop 3 10:00 - 10:50AM Room 251D
Maximizing NGS Library Prep: Enhanced DNA Quantitation, QC, and Size-Selection for Downstream Success
As NGS pushes the boundaries of mutation detection from sub-optimal samples, there is a need for better QC prior to downstream analysis. In addition, the ability to reduce sample loss and more precisely size-select libraries can enhance the probability of successful sequencing of limited, degraded, or potentially contaminated samples. New methods for FFPE and circulating cell-free DNA QC, quantitation, and library size-selection will be discussed in the context of research performed by our speakers, with relevant sequencing metrics and data presented.
Presented by:
Dr. Julie Laliberte of Progenity and Rebecca Peterson of Myriad
Workshop 4 11:00 - 11:50AM Room 251D
Bring Your Assay to Light
An introduction to luciferase technologies in clinical research applications.
Presented by:
Melanie Dart, Senior Research Scientist, Promega Corporation.

Share With a Friend

We will NOT sell your personal information, such as your name or email address, to third parties or use your email address to send you marketing materials. The email and names entered will only be used to identify the sender and recipient of the email.

Send Cancel

Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom